ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
02 août 2023 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
19 juil. 2023 07h00 HE
|
ADMA Biologics, Inc.
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 ...
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
10 mai 2023 16h05 HE
|
ADMA Biologics, Inc.
1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1), Totaling $2.5 Million,...
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
03 mai 2023 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Amendment to Credit Agreement
02 mai 2023 07h00 HE
|
ADMA Biologics, Inc.
Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA...
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
23 mars 2023 16h05 HE
|
ADMA Biologics, Inc.
4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million ...
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
16 mars 2023 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
08 févr. 2023 07h00 HE
|
ADMA Biologics, Inc.
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 ...
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
17 janv. 2023 07h00 HE
|
ADMA Biologics, Inc.
Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately...
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
13 déc. 2022 07h00 HE
|
ADMA Biologics, Inc.
FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life Provides for...